EML4 and lung carcinoma: Crizotinib inhibited the proliferation of AC and KC cells with a median inhibitory concentration (IC50) of 99 and 1187 nM, respectively (Figure 3F), consistent with results obtained with human lung cancer cell lines showing that NCI-H3122 (EML4-ALK positive) was much more sensitive to crizotinib than was A549 (KRASG12S positive) [35].